Loading cancer entity…
Loading cancer entity…
Clinical trials
47 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (5)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07652450 | Incidental Thyroid Cancer in Cases With Inflammatory Thyroid Lesion(Thyroid cancer) | completed | N/A | 98 | Minia UniversityOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT04462471 | Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers | completed | Phase 1 | 8 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT02973997 | Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) | completed | Phase 2 | 57 | Academic and Community Cancer Research UnitedOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT01723202 | Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer | completed | Phase 2 | 53 | Bhavana KondaOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT05410821 | Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer | completed | Phase 1 | 12 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT00381641 | Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery | completed | Phase 2 | 63 | National Cancer Institute (NCI)NIH | 1 | Mar 28, 2025 | clinicaltrials |
| NCT02393690 | Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer | completed | Phase 2 | 60 | Academic and Community Cancer Research UnitedOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT06437873 | Long-term Survival Outcomes of Total Thyroidectomy and Radioactive Iodine Therapy in Unilateral T3/T4 FTC | completed | — | 2,957 | Dezhou Hospital Qilu Hospital of Shandong UniversityOTHER | 0 | May 31, 2024 | clinicaltrials |
| NCT00470496 | Photodynamic Therapy Using HPPH in Treating Patients Undergoing Surgery for Primary or Recurrent Head and Neck Cancer | completed | Phase 1 | 15 | Roswell Park Cancer InstituteOTHER | 1 | Jul 25, 2022 | clinicaltrials |
| NCT05052359 | Aberrant Helix Pomatia Agglutinin Binding Glycan Expression in Follicular Thyroid Tumours | completed | — | 37 | National University Health System, SingaporeOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT01208051 | Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer | completed | Phase 1 / Phase 2 | 127 | National Cancer Institute (NCI)NIH | 2 | Jul 15, 2021 | clinicaltrials |
| NCT01441154 | Metabolic Effects of Synthetic Thyroid Hormone for Thyroid Cancer Treatment | completed | — | 16 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Sep 28, 2020 | clinicaltrials |
| NCT00668811 | Sutent Adjunctive Treatment of Differentiated Thyroid Cancer(IIT Sutent) | completed | Phase 2 | 23 | Medstar Health Research InstituteOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT00104871 | Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Dec 19, 2018 | clinicaltrials |
| NCT00085293 | Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131 | completed | Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2018 | clinicaltrials |
| NCT01811212 | Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Apr 3, 2018 | clinicaltrials |
| NCT00519896 | Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer | completed | Phase 2 | 35 | University of WashingtonOTHER | 1 | Apr 25, 2017 | clinicaltrials |
| NCT00729157 | Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2017 | clinicaltrials |
| NCT00118248 | Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer | completed | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Feb 15, 2017 | clinicaltrials |
| NCT01413113 | Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery | completed | Phase 1 | 6 | University of WashingtonOTHER | 1 | Nov 5, 2015 | clinicaltrials |
| NCT00134043 | Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2014 | clinicaltrials |
| NCT00098813 | Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | May 28, 2014 | clinicaltrials |
| NCT01100619 | A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors | completed | Phase 1 | 40 | ExelixisINDUSTRY | 1 | Sep 19, 2013 | clinicaltrials |
| NCT00004074 | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00068497 | Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer | completed | N/A | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Aug 11, 2026source: clinicaltrials